Systematic Review: GLP-1 Drugs May Reduce Alcohol Consumption, But High-Quality Evidence Is Limited
A systematic review of 6 studies (88,190 participants) found that GLP-1 receptor agonists may reduce alcohol consumption and alcohol-related events, with dulaglutide showing a 29% greater likelihood of reducing intake, but RCT data on exenatide showed no significant effect overall.
Quick Facts
What This Study Found
Exenatide RCT: no significant reduction in heavy drinking days vs placebo overall (95% CI -7.4 to 19.4, p=0.37), but fMRI showed reduced brain reward center cue reactivity in obese subgroup. Dulaglutide secondary analysis: 29% more likely to reduce alcohol intake (relative effect 0.71, CI 0.52-0.97, p=0.04). Observational studies showed fewer alcohol-related healthcare events with GLP-1 RAs.
Key Numbers
Searched multiple databases through August 2024. Included preclinical, observational, and clinical trial data.
How They Did This
Systematic review searching Ovid Medline, EMBASE, PsycINFO, ClinicalTrials.gov, and ProQuest through August 2024. Included 6 studies (88,190 total participants): 2 RCTs (286 participants) and 4 observational studies. Registered with PROSPERO. Assessed alcohol consumption changes, alcohol-related events, healthcare utilization, and fMRI cue reactivity.
Why This Research Matters
Alcohol-related mortality is rising despite available treatments. The unexpected finding that diabetes/obesity drugs might reduce alcohol consumption has generated enormous public interest. This review provides the first comprehensive assessment of the clinical evidence, separating signal from hype.
The Bigger Picture
The possibility that GLP-1 peptide drugs could treat addiction represents a paradigm shift. If confirmed, it would suggest that the reward pathways modulated by GLP-1 receptors extend far beyond appetite — potentially addressing substance use disorders with an entirely new drug class. However, this review shows we're still far from definitive evidence.
What This Study Doesn't Tell Us
Only 286 participants in RCTs — the vast majority (87,904) were from observational studies with inherent confounding. The exenatide RCT was not powered for alcohol as a primary outcome. Heterogeneous study designs, populations, and GLP-1 RA types make synthesis difficult. Publication bias possible in this high-interest area.
Questions This Raises
- ?Does the anti-alcohol effect vary between different GLP-1 RAs (semaglutide vs dulaglutide vs exenatide)?
- ?Is the mechanism primarily through reduced reward signaling, weight loss, or another pathway?
- ?Will the large ongoing RCTs of semaglutide for alcohol use disorder provide definitive answers?
Trust & Context
- Key Stat:
- 29% more likely to reduce alcohol Secondary analysis of a dulaglutide RCT found participants taking the GLP-1 RA were 29% more likely to reduce their alcohol intake compared to placebo
- Evidence Grade:
- Rated preliminary: despite 88,190 participants, only 286 were in RCTs and neither RCT was designed with alcohol as the primary outcome. Observational data is promising but prone to confounding.
- Study Age:
- Published in 2024 with searches through August 2024. Captures the current state of evidence in this rapidly evolving field.
- Original Title:
- Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review.
- Published In:
- EClinicalMedicine, 78, 102920 (2024)
- Authors:
- Subhani, Mohsan, Dhanda, Ashwin, King, James A(3), Warren, Fiona C, Creanor, Siobhan, Davies, Melanie J, Eldeghaidy, Sally, Bawden, Stephen, Gowland, Penny A, Bataller, Ramon, Greenwood, Justin, Kaar, Stephen, Bhala, Neeraj, Aithal, Guruprasad P
- Database ID:
- RPEP-09337
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can Ozempic or similar drugs help people drink less?
Early evidence is intriguing but incomplete. This review found some signals that GLP-1 drugs may reduce alcohol consumption — brain scans showed reduced reward responses, and one trial found a 29% greater chance of cutting back. But the two clinical trials had only 286 participants, and the main exenatide trial showed no significant overall effect. Larger dedicated studies are underway.
Why might a diabetes drug affect alcohol consumption?
GLP-1 receptors are found not just in the pancreas but also in brain regions that control reward and pleasure. These same brain circuits drive both appetite and substance cravings. By dampening reward signaling, GLP-1 drugs might reduce the pleasurable effects of alcohol, making people naturally drink less — though this theory still needs definitive proof.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09337APA
Subhani, Mohsan; Dhanda, Ashwin; King, James A; Warren, Fiona C; Creanor, Siobhan; Davies, Melanie J; Eldeghaidy, Sally; Bawden, Stephen; Gowland, Penny A; Bataller, Ramon; Greenwood, Justin; Kaar, Stephen; Bhala, Neeraj; Aithal, Guruprasad P. (2024). Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review.. EClinicalMedicine, 78, 102920. https://doi.org/10.1016/j.eclinm.2024.102920
MLA
Subhani, Mohsan, et al. "Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review.." EClinicalMedicine, 2024. https://doi.org/10.1016/j.eclinm.2024.102920
RethinkPeptides
RethinkPeptides Research Database. "Association between glucagon-like peptide-1 receptor agonist..." RPEP-09337. Retrieved from https://rethinkpeptides.com/research/subhani-2024-association-between-glucagonlike-peptide1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.